Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 10, 2018 08:35 ET | Source: RespireRX Pharmaceuticals Inc.

RespireRx Pharmaceuticals Inc. Executives Presenting at the International Cannabinoid Derived Pharmaceuticals Summit

December 11 – 12, 2018 Workshops, December 10, 2018 The Revere Hotel 200 Stuart St., Boston, MA SVP R&D leading workshop on Financial Planning and Commercial DevelopmentSVP R&D to present...
September 10, 2018 15:30 ET | Source: RespireRX Pharmaceuticals Inc.

RespireRx Pharmaceuticals Inc. Secures Clinical and Commercial Supply of Dronabinol for Obstructive Sleep Apnea with the Signing of a Development and Supply Agreement with Noramco, Inc.

Glen Rock, N.J., Sept. 10, 2018 (GLOBE NEWSWIRE) -- September 10, 2018 /Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), is pleased to announce that on...
July 25, 2018 09:00 ET | Source: RespireRX Pharmaceuticals Inc.

RespireRx Pharmaceuticals Inc. Announces Publication of Ampakine Data:

Effects of Chronic Systemic Low-impact Ampakine Treatment on Neurotrophin Expression in Rat Brain Glen Rock, N.J., July 25, 2018 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI)...
June 19, 2018 16:14 ET | Source: RespireRX Pharmaceuticals Inc.

RespireRx Pharmaceuticals Inc. Announces Resignation of Dr. James S. Manuso

Glen Rock, N.J, June 19, 2018 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. announces the decision of Dr. James S. Manuso to resign as president, CEO, Vice Chairman and member of the Board of...
June 19, 2018 08:45 ET | Source: RespireRX Pharmaceuticals Inc.

Advancing Dronabinol Obstructive Sleep Apnea Program with Letter of Intent for Co-Development and Supply Agreement with Noramco, Inc.

Glen Rock, N.J., June 19, 2018 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), is pleased to announce that on June 13, 2018, it entered into a letter...
January 08, 2018 08:45 ET | Source: RespireRX Pharmaceuticals Inc.

RespireRx Pharmaceuticals Inc. to Present at 10th Annual Biotech Showcase™ 2018

CEO to Review completed Phase IIB dronabinol trial for the treatment of Obstructive Sleep Apnea (OSA) and Provide Pipeline update Glen Rock, N.J., Jan. 08, 2018 (GLOBE NEWSWIRE) -- RespireRx...
December 18, 2017 08:45 ET | Source: RespireRX Pharmaceuticals Inc.

RespireRx Pharmaceuticals Inc. Publishes Compelling Scientific Evidence Demonstrating the Neurobiological Safety of Ampakine CX717 and Justifying Continued Clinical Development

Glen Rock, N.J., Dec. 18, 2017 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), is pleased to announce that a paper detailing the neurobiologic safety...
December 15, 2017 09:00 ET | Source: RespireRX Pharmaceuticals Inc.

RespireRx Pharmaceuticals Inc. Officers and Directors Elect to Forgive $2,356,733 of Past Due Cash Compensation and Receive Non-Qualified Stock Options to Reduce Balance Sheet Debt

Glen Rock, N.J., Dec. 15, 2017 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC QB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for the treatment of...
November 30, 2017 08:45 ET | Source: RespireRX Pharmaceuticals Inc.

RespireRx Pharmaceuticals Inc. Announces Publication of Phase 2B PACE Study: Once per Night Treatment with Dronabinol Provides Statistically Significant Improvement in Clinical Measures of Obstructive Sleep Apnea

Glen Rock, N.J, Nov. 30, 2017 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”) announces that the results of the PACE (Pharmacotherapy of Apnea by...